Ketamine: The Neuroscience

In 1962 a Parke-Davis chemist named Calvin Stevens synthesised a shorter-acting cousin of the anesthetic PCP, hoping for something gentler. Two years later the anesthesiologist Edward Domino gave it to humans for the first time; volunteers felt detached from their own bodies, and Domino’s wife suggested the word “dissociative.” For three decades ketamine was simply a reliable battlefield and operating-room anesthetic. Then, in 2000, a handful of severely depressed patients received a low dose in a Yale study — and felt better within hours. It was the most important finding in depression research in fifty years, and it came from the unlikeliest of molecules. This is the neuroscience of ketamine: the receptor it blocks, the paradoxical surge it unleashes, the synapses it rebuilds, the medicine it has become, and the deep argument over how it really works.

The Molecule: An Anesthetic That Treats Despair

Ketamine was born as a fix for a problem drug. Its parent compound, PCP, was a powerful anesthetic that left patients agitated and hallucinating for hours; ketamine, synthesised in 1962, kept the pain-killing dissociation but in a far shorter, more manageable form. The FDA approved it as an anesthetic in 1970, and its remarkable safety — it preserves breathing and blood pressure where other anesthetics suppress them — made it a mainstay of battlefield medicine, pediatrics, and veterinary clinics worldwide. The antidepressant story is separate and accidental: at subanesthetic doses, roughly a tenth of what puts someone under, ketamine does something no anesthetic should. The clinical antidepressant dose is about 0.5 mg/kg infused over forty minutes; the same molecule that erases surgical pain at high doses lifts the weight of depression at low ones.

The Receptor: Blocking the Brain’s Main Excitatory Switch

Ketamine’s primary target is the NMDA receptor, the brain’s principal channel for glutamate, the main excitatory neurotransmitter. It is a non-competitive, open-channel blocker: it slips inside the receptor only when the channel is already open and plugs it from within (Anis et al., 1983). This is a fundamentally different mechanism from every classic psychedelic — psilocybin and LSD activate the serotonin 2A receptor, while ketamine blocks a glutamate receptor — and it is why ketamine is called a dissociative rather than a psychedelic. The drug also comes in two mirror-image forms: S-ketamine (esketamine), which binds NMDA roughly three to four times more tightly and is the basis of the approved nasal spray, and R-ketamine (arketamine), which despite weaker NMDA affinity showed longer-lasting antidepressant effects with fewer side effects in rodents — a preclinical surprise now being tested in humans.

The Glutamate Paradox: How Blocking Excitation Excites

Here is the puzzle at the heart of ketamine: how can blocking the brain’s main excitatory receptor produce a surge of excitation? The answer is the disinhibition hypothesis. The NMDA receptors most sensitive to a low dose of ketamine sit not on the main output neurons but on fast-spiking GABA interneurons — the cells whose job is to keep the network in check. Silence the brakes, and the pyramidal neurons they normally restrain fire freely, releasing a brief flood of glutamate (Homayoun & Moghaddam, 2007). That glutamate lands on AMPA receptors, and AMPA activation is the step both major theories agree is essential — block AMPA, and ketamine’s antidepressant effect disappears (Maeng et al., 2008). A second, hotly contested idea goes further: that a ketamine metabolite, hydroxynorketamine (HNK), can drive the antidepressant effect through AMPA without blocking NMDA at all (Zanos et al., 2016, Nature) — a claim other labs have disputed and which remains unresolved. Either way, the destination is the same: a sudden, transient burst of glutamatergic signalling.

Rebuilding the Damaged Brain: Synaptogenesis

That burst is not the cure — it is the trigger for one. In a landmark 2010 Science paper, Ronald Duman’s group showed that a single dose of ketamine rapidly activates the mTOR pathway in the rat prefrontal cortex and grows new dendritic spines — the physical connection points between neurons — within hours; block mTOR with rapamycin and both the new synapses and the behavioural effect vanish (Li et al., 2010). A companion mechanism runs through BDNF, the brain’s key growth factor, whose rapid translation is required for the effect (Autry et al., 2011). This reframes depression itself: chronic stress is associated with the loss of prefrontal synapses, and ketamine appears to rapidly regrow them — later work suggests this spine regrowth is what sustains remission rather than what initiates it (Moda-Sava et al., 2019). It is the defining trait of a psychoplastogen. One crucial caveat: nearly all of this synaptic evidence comes from animal models; the human-brain mechanism is inferred, not directly observed.

The Clinic: From a Yale Pilot to Spravato

The clinical arc is astonishingly fast. In 2000, Robert Berman and John Krystal at Yale reported that ketamine relieved depression within hours in a tiny placebo-controlled trial (Berman et al., 2000). In 2006, Carlos Zarate’s NIMH team confirmed it in treatment-resistant depression: a single dose produced a 71% response within 24 hours, with a very large effect size (Zarate et al., 2006). A 2018 individual-patient meta-analysis found a single infusion reduced suicidal thinking within a day (Wilkinson et al., 2018), though an effect on actual suicide has not been shown. The benefit, however, fades within one to two weeks, which is why clinics give repeated infusions. In 2019 the FDA approved esketamine (Spravato) nasal spray for treatment-resistant depression — the first genuinely new antidepressant mechanism since the SSRIs — followed in 2020 by approval for depression with acute suicidal ideation. Yet the approval drew sharp criticism: only one of three short-term pivotal trials clearly beat placebo, the average advantage was modest, and because saline cannot reproduce ketamine’s dissociation, patients and raters may guess who got the drug — the unresolved “active-placebo” problem (Turner, 2019).

Is the Trip the Medicine? The Dissociation Debate

This is the question the whole field is now circling. Ketamine reliably produces dissociation — a floating detachment from body and self — and early analyses found that the more dissociation a patient felt, the better their antidepressant response (Luckenbaugh et al., 2014). That hinted the experience might be part of the mechanism. But in 2023 a striking trial put it to the test: researchers gave depressed patients ketamine or placebo while they were under general anesthesia for surgery, so no one could consciously experience the drug. Ketamine was no better than placebo (Lii et al., 2023). The result — small and not definitive — suggests that expectancy and the conscious experience may drive more of the benefit than the molecule’s direct chemistry, and that broken blinding may have inflated earlier trials. Whether ketamine’s antidepressant power lies in the synapses, the subjective journey, or both, is genuinely open.

The Brain on Ketamine, and Its Risks

Imaging fills in the picture: ketamine alters connectivity in the default mode network, the self-referential midline system (Scheidegger et al., 2012); acutely increases global connectivity and cortical gamma oscillations through the same disinhibition that drives the glutamate surge (Driesen et al., 2013; Shaw et al., 2015); and transiently raises glutamate markers in the anterior cingulate. But the risks are real and rise steeply with unmonitored, repeated use. Chronic recreational ketamine causes a severe, sometimes irreversible bladder disease — ketamine cystitis (Shahani et al., 2007) — along with measurable cognitive deficits in heavy users (Morgan et al., 2010) and genuine psychological dependence (Morgan & Curran, 2012). It is a Schedule III controlled substance, and the gulf between a monitored 0.5 mg/kg clinical infusion and high-dose recreational bingeing is enormous. The recent, widely reported death of actor Matthew Perry — ruled an accident from the acute effects of ketamine — underscored how dangerous the drug becomes outside clinical supervision. This article is education, not medical advice.

The Synthesis

Ketamine broke every rule. It treats despair through a receptor no one was looking at, works in hours instead of weeks, and seems to heal by rebuilding the brain’s physical wiring rather than nudging its chemistry. It turned a sixty-year-old anesthetic into the template for a new generation of rapid antidepressants and forced a rethink of what depression even is — less a chemical imbalance than a disease of lost connections. And it left the field with a profound, unfinished question: when a drug both rewires the brain and dissolves the self, which one is doing the healing? The honest answer, for now, is that we are still finding out — and that ketamine, for all its promise, demands the same respect, caution, and clinical care as any tool powerful enough to change a mind in an afternoon.